Prognostic biomarkers in malignant lymphomas.
There has recently been a rapid expansion in research aimed at identifying biomarkers that could improve the prognosis for patients with various subtypes of malignant lymphoma. Genomic and genetic studies have led to the identification of biological and clinical subgroups of diffuse large B-cell lymphomas with distinct underlying molecular features, divergent activation of oncogenetic pathways, and clinical course. Molecular studies of follicular lymphoma have suggested complex interactions between malignant cells and the surrounding immunological network that could affect disease progression. Moreover, the inflammatory cells of Hodgkin lymphoma have been shown to produce a complex network of cytokines and chemokines that provide a permissive microenvironment for tumor growth. Research into specific biomarkers and signaling pathways of malignant lymphomas might therefore result in the identification of novel targets for future therapeutic strategies. As gene expression profiling techniques are not yet feasible in the clinical laboratory, studies have aimed to translate the findings into more widely applicable techniques that might allow this research to be applied to routine clinical practice. This review focuses on recent advances in translational and clinical research on biomarkers in malignant lymphomas.
Gascoyne
Randy D
RD
British Columbia Cancer Agency, Department of Pathology and Experimental Therapeutics, Vancouver, BC, Canada. rgascoyn@bccancer.bc.ca
Rosenwald
Andreas
A
Poppema
Sibrand
S
Lenz
Georg
G
D014408:Biomarkers, Tumor; D020869:Gene Expression Profiling; D006801:Humans; D008223:Lymphoma / Q000175:diagnosis*; D011379:Prognosis
D014408:Biomarkers, Tumor